Syndax Pharmaceuticals, Inc. SNDX | NASDAQ
|2026-09-09
Company Overview:
10 Year SNDX Performance Metrics:
Build Custom Charts
SNDX Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for SNDX
Based on past 10-year performance, here are SNDX growth metrics:
Share price CAGR of -0.77%
Dividend CAGR of +0%
Using SNDX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| SNDX (DRIP) | SNDX - No DRIP | |
|---|---|---|
| Current Price | $9.35 | $9.35 |
| Start Shares | 1,069.52 | 1,069.52 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 1,069.52 | 1,069.52 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $8.66 | $9.35 |
| Total Dividends | $0 | $0 |
| Final Value | $9,257 | $10,000 |
NOTE: Above numbers are our estimate based on SNDX's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Syndax Pharmaceuticals, Inc. (SNDX) had its IPO on 2016-03-02, and is traded on NASDAQ stock exchange.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
SNDX website: https://www.syndax.com
DCF Model — SNDX
FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.
EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.
| Year | FCF | Implied price |
|---|
